Abstract
Background: Psoriasis is a chronic immune mediated disease that is considered to be a multisystem disease that extends beyond the limits of the skin to affect other tissues and organs, possibly associated with enhanced atherosclerosis and risk of coronary artery disease. Objective: The aim of this work is to evaluate the serum level of soluble p-selectin and leptin serum levels in patients with psoriasis and their possible relation to the cardiovascular risk factors in those patients also the relation between their levels and the clinical severity of the disease Patients and methods: This study was carried on seventy patients with chronic moderate to severe psoriasis. forty of them (group A) were excluded from disorders affecting platelet activity, and compared to 20 healthy age and sex matched control subjects (control A), both groups were studied for serum soluble P-selectin level, The other thirty patients (group B) were excluded from disorders affecting serum leptin level, and compared to thirty healthy age and sex matched control subjects (control B) both groups were studied for serum leptin level. Results: soluble P-selectin level is significantly increased in psoriatic patients in the group A in comparison to control A subjects, and there was a significant increase in serum leptin level psoriatic patients in the group B in comparison to the control B subjects. Serum leptin and soluble P-selectin levels showed a positive correlation with Psoriasis Area and Severity Index. Conclusion: Soluble p-selectin is a marker of platelet activation and has an impact on psoriasis activity; also it can be used as a marker of psoriasis severity. Leptin is an adipose tissue derived hormone that was suggested to have a role in pathogenesis of psoriasis whether through its inflammatory role or through its permissive effect on the development of psoriasis associated metabolic risk factors.
Highlights
Psoriasis is a chronic, autoimmune, noncontagious, multisystem, hyperproliferative, inflammatory disorder with significant comorbidities that affects 1% to 4% of the world’s population
The mean of Psoriasis Area and Severity Index (PASI) of patients in this group was 20.32 ± 11.93 before NB-UVB and 6.83 ± 10.69 after NB-UVB They were chosen with normal body mass index with a mean of 26.20 ± 2.96 and excluded from hypertension, dyslipidemia, or diabetes. no family history of heart disease and by investigation those patients were chosen with normal LDL, serum cholesterol, serum triglycerides, high density lipoprotein (HDL) and platelet count, so excluding factors that affect serum soluble P-selectin levels
At the same time it has a positive correlation with diabetes, hypertension and hypertriglyceridemia and body mass index (BMI), those serve separately as a cardiovascular risk factor
Summary
Autoimmune, noncontagious, multisystem, hyperproliferative, inflammatory disorder with significant comorbidities that affects 1% to 4% of the world’s population. It is a complex, multifactorial disease that appears to be influenced by genetic, environmental factors, vascular and immune-mediated components [1]. Compared with the general population, Psoriasis is associated with increased risk of major adverse cardiac events, patients with psoriasis appear to be more likely to develop hypertension, diabetes mellitus, obesity, and dyslipidemia compared with the general population [2,3,4]. Psoriasis is a chronic immune mediated disease that is considered to be a multisystem disease that extends beyond the limits of the skin to affect other tissues and organs, possibly associated with enhanced atherosclerosis and risk of coronary artery disease
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
